Triheptanoin Did Not Show Benefit versus Placebo for the Treatment of Paroxysmal Movement Disorders in Glut1 Deficiency Syndrome: Results of a Randomized Phase 3 Study DOI Creative Commons
Valentina De Giorgis, Kailash P. Bhatia, Odile Boespflug‐Tanguy

et al.

Movement Disorders, Journal Year: 2024, Volume and Issue: 39(8), P. 1386 - 1396

Published: May 9, 2024

Abstract Background Paroxysmal movement disorders are common in Glut1 deficiency syndrome (Glut1DS). Not all patients respond to or tolerate ketogenic diets. Objectives The objective was evaluate the effectiveness and safety of triheptanoin reducing frequency disabling with Glut1DS not receiving a diet. Methods UX007G‐CL301 randomized, double‐blind, placebo‐controlled, phase 3 crossover study. After 6‐week run‐in, eligible were randomized 1:1 first sequence (triheptanoin/placebo placebo/triheptanoin) titration plus maintenance, followed by washout opposite maintenance. placebo (safflower oil) matched appearance, taste, smell triheptanoin. Open‐label administered extension. paroxysmal disorder events per 4 weeks (recorded diary during maintenance; primary endpoint) assessed Wilcoxon rank‐sum test. Results Forty‐three (children, n = 16; adults, 27) treated. There no difference between mean (interquartile range) number (14.3 [4.7–38.3] vs. 11.8; [3.2–28.7]; Hodges‐Lehmann estimated median difference: 1.46; 95% confidence interval, −1.12 4.36; P 0.2684). Treatment‐emergent adverse mild/moderate severity included diarrhea, vomiting, upper abdominal pain, headache, nausea. Two discontinued study because non‐serious that predominantly gastrointestinal. closed early open‐label extension lack effectiveness. Seven continued receive compassionately. Conclusion significant differences groups double‐blind maintenance period. © 2024 Authors. Movement Disorders published Wiley Periodicals LLC on behalf International Parkinson Disorder Society.

Language: Английский

ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions DOI
Sameer M. Zuberi, Elaine Wirrell, Elissa Yozawitz

et al.

Epilepsia, Journal Year: 2022, Volume and Issue: 63(6), P. 1349 - 1397

Published: May 3, 2022

Abstract The International League Against Epilepsy (ILAE) Task Force on Nosology and Definitions proposes a classification definition of epilepsy syndromes in the neonate infant with seizure onset up to 2 years age. incidence is high this age group frequently associated significant comorbidities mortality. licensing syndrome specific antiseizure medications following randomized controlled trials development precision, gene‐related therapies are two drivers defining electroclinical phenotypes infancy. principal aim proposal, consistent 2017 ILAE Classification Epilepsies, support diagnosis emphasize importance classifying an individual both by etiology. For each syndrome, we report epidemiology, clinical course, types, electroencephalography (EEG), neuroimaging, genetics, differential diagnosis. Syndromes separated into self‐limited syndromes, where there likely be spontaneous remission developmental epileptic encephalopathies , diseases impairment related underlying etiology independent epileptiform activity encephalopathy. emerging class etiology‐specific for that clearly defined, relatively uniform, distinct phenotype most affected individuals as well EEG, and/or genetic correlates, presented. number etiology‐defined will continue increase, these newly described time incorporated classification. tables summarize mandatory features, cautionary alerts, exclusionary features common syndromes. Guidance given criteria resource‐limited regions laboratory confirmation, including MRI, testing, might not available.

Language: Английский

Citations

541

Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed? DOI Open Access

Suzanne E. Engelen,

Alice Robinson, Yasemin-Xiomara Zurke

et al.

Nature Reviews Cardiology, Journal Year: 2022, Volume and Issue: 19(8), P. 522 - 542

Published: Jan. 31, 2022

Language: Английский

Citations

258

Glut1 Deficiency Syndrome (Glut1DS): State of the art in 2020 and recommendations of the international Glut1DS study group DOI Creative Commons
Joerg Klepper, Cigdem I. Akman, Marisa Armeno

et al.

Epilepsia Open, Journal Year: 2020, Volume and Issue: 5(3), P. 354 - 365

Published: June 27, 2020

Glut1 deficiency syndrome (Glut1DS) is a brain energy failure caused by impaired glucose transport across tissue barriers. Glucose diffusion barriers facilitated family of proteins including transporter type 1 (Glut1). Patients are treated effectively with ketogenic diet therapies (KDT) that provide supplemental fuel, namely ketone bodies, for metabolism. The increasing complexity Glut1DS, since its original description in 1991, now demands an international consensus statement regarding diagnosis and treatment. International experts (n = 23) developed utilizing their collective professional experience, responses to standardized questionnaire, serial discussions wide-ranging issues related Glut1DS. Key clinical features signaling the onset Glut1DS eye-head movement abnormalities, seizures, neurodevelopmental impairment, deceleration head growth, disorders. Diagnosis confirmed presence these signs, hypoglycorrhachia documented lumbar puncture, genetic analysis showing pathogenic

Language: Английский

Citations

203

Brain energy metabolism: A roadmap for future research DOI Creative Commons
Caroline Rae, Joseph A. Baur, Karin Borges

et al.

Journal of Neurochemistry, Journal Year: 2024, Volume and Issue: 168(5), P. 910 - 954

Published: Jan. 6, 2024

Although we have learned much about how the brain fuels its functions over last decades, there remains still to discover in an organ that is so complex. This article lays out major gaps our knowledge of interrelationships between metabolism and function, including biochemical, cellular, subcellular aspects functional imaging adult brain, as well during development, aging, disease. The focus on unknowns substrates associated transporters, roles insulin lipid droplets, emerging role microglia, mysteries cofactor signaling molecule NAD

Language: Английский

Citations

35

Clinical Management of Drug Resistant Epilepsy: A Review on Current Strategies DOI Creative Commons
Déborah Guery, Sylvain Rheims

Neuropsychiatric Disease and Treatment, Journal Year: 2021, Volume and Issue: Volume 17, P. 2229 - 2242

Published: July 1, 2021

Abstract: Drug resistant epilepsy (DRE) is defined as the persistence of seizures despite at least two syndrome-adapted antiseizure drugs (ASD) used efficacious daily dose. Despite increasing number available ASD, about a third patients with still suffer from drug resistance. Several factors are associated risk evolution to DRE in newly diagnosed epilepsy, including onset infancy, intellectual disability, symptomatic and abnormal neurological exam. Pharmacological management often consists ASD polytherapy. However, because quality life driven by several DRE, tolerability treatment, should try optimize efficacy while anticipating risks drug-related adverse events. All be evaluated once tertiary center, especially discuss eligibility for non-pharmacological therapies. This paramount importance focal whom surgery can result long-term seizure freedom. Vagus nerve stimulation, deep brain stimulation or cortical also improve control. Lastly, considering effect on psychologic status social integration, comprehensive care adaptations always needed order patients' life. Keywords: surgery, drugs,

Language: Английский

Citations

77

Current practice in diagnostic genetic testing of the epilepsies DOI Creative Commons
Ilona Krey, Konrad Platzer, Alina Esterhuizen

et al.

Epileptic Disorders, Journal Year: 2022, Volume and Issue: 24(5), P. 765 - 786

Published: July 13, 2022

Epilepsy genetics is a rapidly developing field, in which novel disease-associated genes, mechanisms associated with epilepsy, and precision medicine approaches are continuously being identified. In the past decade, advances genomic knowledge analysis platforms have begun to make clinical genetic testing accessible for, principle, people of all ages epilepsy. For this reason, Genetics Commission International League Against (ILAE) presents update on practice, including current techniques, indications, yield testing, recommendations for pre- post-test counseling, follow-up after completed. We acknowledge that resources vary across different settings but highlight diagnostic epilepsy should be prioritized when likelihood an informative finding high. Results particular identification causative variants, likely improve individual care. emphasize importance individuals as we enter era therapy.

Language: Английский

Citations

67

Migraine, Brain Glucose Metabolism and the “Neuroenergetic” Hypothesis: A Scoping Review DOI Creative Commons
Lorenzo Del Moro, Eugenia Rota, Elenamaria Pirovano

et al.

Journal of Pain, Journal Year: 2022, Volume and Issue: 23(8), P. 1294 - 1317

Published: March 14, 2022

Increasing evidence suggests that migraine may be the result of an impaired brain glucose metabolism. Several studies have reported mitochondrial dysfunction, metabolism and gray matter volume reduction in specific areas migraineurs. Furthermore, peripheral insulin resistance, a condition demonstrated several studies, extend to brain, leading resistance. This has been proven downregulate receptors, both astrocytes neurons, triggering uptake glycogen synthesis, mainly during high metabolic demand. scoping review examines clinical, epidemiologic pathophysiologic data supporting hypothesis abnormalities generate mismatch between brain's energy reserve expenditure, attacks. Moreover, alteration homeostasis could chronic deficit promoting chronification. Lastly, resistance link with its comorbidities, like obesity, depression, cognitive impairment cerebrovascular diseases.PerspectiveAlthough additional experimental are needed support this novel “neuroenergetic” hypothesis, migraineurs unravel pathophysiological mechanisms disease, explaining chronification connecting comorbidities. Therefore, elucidate potential approaches for treatment.

Language: Английский

Citations

39

Transporter-Mediated Drug Delivery DOI Creative Commons
Gergely Gyimesi, Matthias A. Hediger

Molecules, Journal Year: 2023, Volume and Issue: 28(3), P. 1151 - 1151

Published: Jan. 24, 2023

Transmembrane transport of small organic and inorganic molecules is one the cornerstones cellular metabolism. Among transmembrane transporters, solute carrier (SLC) proteins form largest, albeit very diverse, superfamily with over 400 members. It was recognized early on that xenobiotics can directly interact SLCs this interaction fundamentally determine their efficacy, including bioavailability intertissue distribution. Apart from well-established prodrug strategy, chemical ligation transporter substrates to nanoparticles various compositions has recently been used as a means enhance targeting absorption. In review, we summarize efforts in drug design exploiting interactions specific SLC transporters optimize therapeutic effects. Furthermore, describe current future challenges well new directions for advanced development therapeutics target transporters.

Language: Английский

Citations

34

Transcellular Barriers to Glucose Delivery in the Body DOI Creative Commons
Amira Klip, Katrien De Bock, Philip J. Bilan

et al.

Annual Review of Physiology, Journal Year: 2024, Volume and Issue: 86(1), P. 149 - 173

Published: Feb. 12, 2024

Glucose is the universal fuel of most mammalian cells, and it largely replenished through dietary intake. availability to tissues paramount for maintenance homeostatic energetics and, hence, supply should match demand by consuming organs. In its journey body, glucose encounters cellular barriers transit at levels absorbing intestinal epithelial wall, renal epithelium mediating reabsorption, tight capillary endothelia (especially in brain). transiting these must escape degradation ensure optimal delivery bloodstream or tissues. The liver, which stores glycogen generates de novo, similarly be able release intact circulation. We present up-to-date knowledge on handling gut, brain endothelium, kidney, discuss underlying molecular mechanisms open questions. Diseases associated with defects homeostasis are also briefly addressed. propose that problem sparing from catabolism favor translocation across posed epithelia resolved common involving transfer endoplasmic reticulum, where exits cells via unconventional mechanisms.

Language: Английский

Citations

10

Glucose Transporter 1 Deficiency Impairs Glucose Metabolism and Barrier Induction in Human Induced Pluripotent Stem Cell‐Derived Astrocytes DOI
Iqra Pervaiz,

Yash Mehta,

Abraham Al‐Ahmad

et al.

Journal of Cellular Physiology, Journal Year: 2025, Volume and Issue: 240(1)

Published: Jan. 1, 2025

Glucose is a major source of energy for the brain. At blood-brain barrier (BBB), glucose uptake facilitated by transporter 1 (GLUT1). GLUT1 Deficiency Syndrome (GLUT1DS), haploinsufficiency affecting SLC2A1, reduces brain uptake. A lot effort has been made to characterize GLUT1DS at BBB, but impact on astrocytes remains unclear. In this study, we investigated astrocyte differentiation and function in vitro, using human induced pluripotent stem cells (GLUT1DS-iPSCs) differentiated into astrocyte-like (iAstros). expression decreased during iPSCs astrocytes, with neural progenitor showing lowest expression. The presence truncated did not compromise iAstros, as these could express several key markers representative lineage. GLUT1DS-iAstros failed full-length protein levels while no signs impaired GLUT4 However, showed lactate production compared control-iAstros, reduced glycolysis, mitochondrial activity well ATP deficit. addition production, displayed extracellular glutamate release. As previously observed, one iAstros clone (C7) most severe phenotype from all groups. Our study provides an insightful view contribution astrocytes' energetic metabolism raises possible astrocyte-neuron metabolic coupling. future direction understand better how impacts neurons within their

Language: Английский

Citations

1